Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) patients have not been investigated. Etidronate, another bisphosphonate, can suppress the extent of coronary artery calcification in chronic hemodialysis patients. The hypothesis of this study is that alendronate can increase bone mineral density and suppress aortic and coronary artery calcification in chronic peritoneal dialysis patients.
| Condition | Intervention | Phase |
|---|---|---|
|
End-Stage Renal Disease Osteoporosis |
Drug: alendronate |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? |
- extent of aortic and coronary artery calcification with and without the use of alendronate
- bone mineral density with and without the use of alendronate
- serum levels of calcium, phosphorus and parathyroid hormone
| Estimated Enrollment: | 50 |
| Study Start Date: | August 2005 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Study Design
The study is a prospective, randomized cross-over study. Fifty patients will be included. All participants are randomly allocated to either group 1 or group 2. Each group consists of 25 patients. Group 1 patients receive alendronate 70 mg once weekly in the first 24 weeks of the study, while group 2 patients receive the same dose of drug every week in the second 24 weeks. The extent of coronary artery and aortic calcification is evaluated by using multidetector spiral computed tomography, whereas bone mineral density is measured by dual-energy X-ray absorptiometry. Both examinations are performed at week 0, 24 and 48 for each participant. Serum level of calcium should be kept within normal limits and serum level of phosphorus should be kept below 6 mg/dl.
Administration of Alendronate
One tablet of alendronate (70 mg per tablet) should be swallowed by each patient once every week with water at least 30 minutes before breakfast, beverage or medication of the day during the treatment period. Patients must not lie down for at least 30 minutes after taking the drug.
Measurement of Coronary Artery and Aortic Calcification
Multidetector spiral computerized tomography (CT) of the chest is performed at week 0, 24 and 48 for each participant to measure the extent of coronary and aortic calcification.
Measurement of Bone Density
Dual energy X-ray absorptiometry is performed at week 0, 24 and 48 for each participant to measure the density of bone.
Demographic and Clinical Characteristics of Patients
Patients characteristics such as age and sex are documented. Clinical parameters including body height, body weight, duration of dialysis, calcium concentration of dialysate, and medication under use are recorded. Blood pressure is measured at each clinical visit for 3 times after the patient has sit for at least 15 minutes.
Collection of Laboratory Data
Fasting serum levels of albumin, phosphorus, calcium, alkaline phosphatase (ALP), intact parathyroid hormone (iPTH) and hemoglobin level of each patient are checked at study entry and once every month. Fasting serum levels of triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-chol), low-density lipoprotein cholesterol (LDL-chol), and hypersensitive C-reactive protein (CRP) of each patient are checked at study entry and once every 3 months.
Record of Adverse Effects of Alendronate
Any adverse effect of alendronate is recorded every month at clinic visit.
Compliance of Patients
Compliance of the patients is monitored using telephone calls once every week during the treatment period with alendronate.
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have received maintenance PD for more than 3 months at National Taiwan University Hospital,
- Have high CPP level (≧50), and
- Have chest X-ray proven aortic calcification or coronary artery calcification proven before.
Exclusion Criteria:
Patients are excluded if they have any one of the following conditions:
- Had been hospitalized in recent 3 months due to severe comorbid diseases,
- Are hypersensitive to alendronate or any of its components,
- Have esophageal diseases
- Are not able to stand or sit upright for 30 minutes,
- Have refractory hypocalcemia, or
- Patients who are pregnant.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00261625 History of Changes |
| Other Study ID Numbers: | 940706 |
| Study First Received: | December 1, 2005 |
| Last Updated: | January 2, 2009 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by National Taiwan University Hospital:
|
peritoneal dialysis artery calcification bone mineral density |
Additional relevant MeSH terms:
|
Calcinosis Kidney Diseases Kidney Failure, Chronic Osteoporosis Calcium Metabolism Disorders Metabolic Diseases Urologic Diseases Renal Insufficiency, Chronic |
Renal Insufficiency Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Alendronate Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013